Sun Feb 10, 2013, 06:16 PM
WillyT (72,631 posts)
Genetically Engineered Virus Kills Cancer: Study - AFP/Rawstory
Genetically engineered virus kills cancer: study
By Agence France-Presse/RawStory
Sunday, February 10, 2013 13:53 EST
A genetically-engineered virus tested in 30 terminally-ill liver cancer patients significantly prolonged their lives, killing tumours and inhibiting the growth of new ones, scientists reported on Sunday.
Sixteen patients given a high dose of the therapy survived for 14.1 months on average, compared to 6.7 months for the 14 who got the low dose. “For the first time in medical history we have shown that a genetically-engineered virus can improve survival of cancer patients,” study co-author David Kirn told AFP.
The four-week trial with the vaccine Pexa-Vec or JX-594, reported in the journal Nature Medicine, may hold promise for the treatment of advanced solid tumours.
“Despite advances in cancer treatment over the past 30 years with chemotherapy and biologics, the majority of solid tumours remain incurable once they are metastatic (have spread to other organs),” the authors wrote. There was a need for the development of “more potent active immunotherapies”, they noted.
Pexa-Vec “is designed to multiply in and subsequently destroy cancer cells, while at the same time making the patients’ own immune defence system attack cancer cells also,” said Kirn from California-based biotherapy company Jennerex.
“The results demonstrated that Pexa-Vec treatment at both doses resulted in a reduction of tumour size and decreased blood flow to tumours,” said a Jennerex statement. “The data further demonstrates that Pexa-Vec treatment induced an immune response against the tumour.”
1 replies, 719 views
Always highlight: 10 newest replies | Replies posted after I mark a forum
Replies to this discussion thread
Genetically Engineered Virus Kills Cancer: Study - AFP/Rawstory (Original post)
Response to WillyT (Original post)
Sun Feb 10, 2013, 07:17 PM
farminator3000 (2,115 posts)
1. Marijuana And Cancer: Scientists Find Cannabis Compound Stops Metastasis In Aggressive Cancers
Last edited Mon Feb 11, 2013, 10:04 AM - Edit history (1)
"What we found was that his Cannabidiol could essentially 'turn off' the ID-1," Desprez told HuffPost. The cells stopped spreading and returned to normal.
"We likely would not have found this on our own," he added. "That's why collaboration is so essential to scientific discovery."
Desprez and McAllister first published a paper about the finding in 2007. Since then, their team has found that CBD works both in the lab and in animals. And now, they've found even more good news.
"We started by researching breast cancer," said Desprez. "But now we've found that Cannabidiol works with many kinds of aggressive cancers--brain, prostate--any kind in which these high levels of ID-1 are present."
Desprez hopes that clinical trials will begin immediately.
"We've found no toxicity in the animals we've tested, and Cannabidiol is already used in humans for a variety of other ailments," he said. Indeed, the compound is used to relieve anxiety and nausea, and, since it is non-psychoactive, does not cause the "high" associated with THC.
While marijuana advocates will surely praise the discovery, Desprez explained that it's not so easy as just lighting up.
"We used injections in the animal testing and are also testing pills," he said. "But you could never get enough Cannabidiol for it to be effective just from smoking."
Furthermore, the team has started synthesizing the compound in the lab instead of using the plant in an effort to make it more potent.
"It's a common practice," explained Desprez. "But hopefully it will also keep us clear of any obstacles while seeking approval."
that part about not enough from smoke- obviously you don't smoke when you have cancer- you EAT the weed, duh.
you can definitely eat enough, esp. if you make hash.
sucks that they have to synthesize it because the laws are so idiotic.
now, why would the scientist ignore cannabis and try to GE viruses? oh, right.
After joining Onyx as the first oncology development employee, he created and initiated clinical development plans in partnership with Bayer for Nexavar, now a marketed product for kidney and liver cancers. He also led the development of a first-in-class oncolytic virus therapeutic through to Phase 3, a corporate partnership with Warner-Lambert and an initial public offering during his tenure. He has been a consultant in cancer biotherapeutics for Pfizer, Novartis, BiogenIdec, Schering AG and other leading oncology companies.
Sixteen patients given a high dose of the therapy survived for 14.1 months on average, compared to 6.7 months for the 14 who got the low dose.
plus, it doesn't seem to work that well, compared to a complete cure from natural CBD.